Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET

Company Participants

Donald Notman – Chief Financial Officer

Antony Mattessich – President and Chief Executive Officer

Rabia Ozden – Chief Medical Officer

Peter Kaiser – Chief Medical Adviser-Retina

Conference Call Participants

Joe Catanzaro – Piper Sandler

Kambiz Yazdi – Jefferies

Yi Chen – H.C. Wainwright

Yuan Zhi – B. Riley

Georgi Yordanov – Cowen

Caroline Palomeque – Berenberg

Operator

Good day, and thank you for standing by. Welcome to the Ocular Therapeutix Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to hand it over our conference to your speaker today, Donald Notman, the CFO. Go ahead, Donald.

Donald Notman

Thank you, operator. Good afternoon, everyone, and thank you for joining us on our third quarter 2022 financial results and business update conference call. This afternoon, after the close, we issued a press release providing an update on the company’s product development programs and details of the company’s financial results for the third quarter ended September 30, 2022. The press release can be accessed on the Investors portion of our website at investors.ocutx.com.

Leading the call today will be Antony Mattessich, our President and Chief Executive Officer, who will provide an update on our pipeline developments and the commercial progress of DEXTENZA. Also speaking on the call today will be Dr. Rabia Ozden, our Chief Medical Officer; and Dr. Peter Kaiser, our Chief Medical Adviser, Retina. Following their remarks, I will provide an overview of the financial highlights for the quarter before turning the call back over to Antony for a summary and questions. For Q&A, we will also be joined by Chris White, our Chief Business Officer; and Scott Corning, our Senior Vice President, Commercial.

As a reminder, on today’s call, certain statements we will be making may be considered forward-looking for purposes of the Private Securities Litigation Reform Act of 1995. In particular, any statements regarding our regulatory and product development plans as well as our research activities and our financial projections are forward-looking statements.

These statements are subject to a variety of risks and uncertainties that may cause actual results to differ from those forecasted, including those risks described in our most recent quarterly report filed this afternoon with the SEC and our Annual Report on Form 10-K filed on February 28 with the SEC.